Overview

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: - Trastuzumab-emtansine (T-DM1, Kadcyla) - Trastuzumab SC (Herceptin Hylecta) - Paclitaxel
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Genentech, Inc.
Treatments:
Ado-Trastuzumab Emtansine
Maytansine
Paclitaxel
Trastuzumab